纳米医学
洛比那韦
药物发现
人类免疫缺陷病毒(HIV)
医学
药品
纳米技术
重症监护医学
抗逆转录病毒疗法
药理学
生物信息学
纳米颗粒
病毒载量
病毒学
材料科学
生物
作者
Marco Giardiello,Neill J. Liptrott,Tom O. McDonald,Darren Michael Moss,Marco Siccardi,Phil Martin,Darren Smith,Rohan Gurjar,Steve P. Rannard,Andrew Owen
摘要
Considerable scope exists to vary the physical and chemical properties of nanoparticles, with subsequent impact on biological interactions; however, no accelerated process to access large nanoparticle material space is currently available, hampering the development of new nanomedicines. In particular, no clinically available nanotherapies exist for HIV populations and conventional paediatric HIV medicines are poorly available; one current paediatric formulation utilizes high ethanol concentrations to solubilize lopinavir, a poorly soluble antiretroviral. Here we apply accelerated nanomedicine discovery to generate a potential aqueous paediatric HIV nanotherapy, with clinical translation and regulatory approval for human evaluation. Our rapid small-scale screening approach yields large libraries of solid drug nanoparticles (160 individual components) targeting oral dose. Screening uses 1 mg of drug compound per library member and iterative pharmacological and chemical evaluation establishes potential candidates for progression through to clinical manufacture. The wide applicability of our strategy has implications for multiple therapy development programmes.
科研通智能强力驱动
Strongly Powered by AbleSci AI